Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pozelimab - Regeneron Pharmaceuticals

Next Previous
Drug Profile

Pozelimab - Regeneron Pharmaceuticals

Alternative Names: Pozelimab-bbfg; REGN 3918; Veopoz

Latest Information Update: 20 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Regeneron Pharmaceuticals
  • Developer Alnylam Pharmaceuticals; Regeneron Pharmaceuticals
  • Class Anti-inflammatories; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Complement C5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Paroxysmal nocturnal haemoglobinuria; Protein-losing enteropathy
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Protein-losing enteropathy
  • Phase III Dry macular degeneration; Myasthenia gravis; Paroxysmal nocturnal haemoglobinuria

Most Recent Events

  • 17 Nov 2025 Regeneron Pharmaceuticals plans a phase I trial for Dry macular degeneration (Intravitreous, Injection) in December 2025 (NCT07230834) (EudraCT2025-521758-40-00)
  • 26 Aug 2025 Launched for Protein-losing enteropathy (In adults, In children, In the elderly, In infants, In adolescents) in USA (IV) prior to August 2025 (NCT07142343)
  • 26 Aug 2025 Launched for Protein-losing enteropathy (In infants, In children, In the elderly, In adolescents, In adults) in USA (SC) prior to August 2025 (NCT07142343)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top